APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 0.1-0.3μg/ml |
| 3-5μg/ml |
|
Note :
IHC-P
Human Skeletal Muscle shows peripheral staining of fibres.
|
Not tested in other applications.
Calculated MW
Positive Control
The peptide used to generate this antibody is available for purchase (GTX88437-PEP).
Predict Reactivity
Bovine, Dog(>80% identity)
PROPERTIES
Form
Liquid
Buffer
TBS, 0.5% BSA
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.50 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Peptide with sequence EHTDLEAQIVKDIH-C, from the N Terminus of the protein sequence according to NP_203123.1.
Purification
Purified by ammonium sulphate precipitation followed by antigen affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
caveolin 3 , LGMD1C , LQT9 , MPDT , RMD2 , VIP-21 , VIP21
Cellular Localization
Golgi apparatus membrane , Cell membrane
Background
This gene encodes a caveolin family member, which functions as a component of the caveolae plasma membranes found in most cell types. Caveolin proteins are proposed to be scaffolding proteins for organizing and concentrating certain caveolin-interacting molecules. Mutations identified in this gene lead to interference with protein oligomerization or intra-cellular routing, disrupting caveolae formation and resulting in Limb-Girdle muscular dystrophy type-1C (LGMD-1C), hyperCKemia or rippling muscle disease (RMD). Alternative splicing has been identified for this locus, with inclusion or exclusion of a differentially spliced intron. In addition, transcripts utilize multiple polyA sites and contain two potential translation initiation sites. [provided by RefSeq, Jul 2008]
Database
Research Area
DATA IMAGES
|
GTX88437 WB Image
WB analysis of mouse (A) and rat (B) heart lysates using GTX88437 Caveolin 3 antibody, N-term.
Dilution : 0.3μg/ml
Loading : 35μg protein in RIPA buffer
|
|
|
GTX88437 WB Image
WB analysis of human heart lysate using GTX88437 Caveolin 3 antibody, N-term.
Dilution : 0.3μg/ml
Loading : 35μg protein in RIPA buffer
|
|
|
GTX88437 WB Image
WB analysis of pig skeletal muscle (A) and heart (B) lysates using GTX88437 Caveolin 3 antibody, N-term.
Dilution : 0.1μg/ml
Loading : 35μg protein in RIPA buffer
|
|
|
GTX88437 IHC-P Image
IHC-P analysis of human skeletal muscle using GTX88437 Caveolin 3 antibody, N-term.
Antigen retrieval : citrate buffer pH 6
Dilution : 3.8μg/ml
|
REFERENCE
There are currently no references for Caveolin 3 antibody, N-term (GTX88437). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for Caveolin 3 antibody, N-term (GTX88437). Be the first to share your experience with this product.
